Identifying potential repurposable medications for Parkinson's disease through Mendelian randomization analysis

被引:0
作者
Wang, Qitong [1 ]
Liu, Fang [1 ]
Wang, Xinyu [1 ]
Zhong, Lifan [1 ]
Cai, Benchi [1 ]
Chen, Tao [1 ,2 ]
机构
[1] Hainan Med Univ, Hainan Affiliated Hosp, Hainan Gen Hosp, Dept Neurol, Haikou 570311, Hainan, Peoples R China
[2] Hainan Prov Bur Dis Prevent & Control, Haikou 570100, Peoples R China
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
基金
中国国家自然科学基金;
关键词
Medication; Parkinson's disease; Mendelian randomization; Genetic epidemiology; TRIAL; DISORDERS; CALCIUM; NEURONS;
D O I
10.1038/s41598-024-70758-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Observational studies have suggested the potential benefits of several medications for Parkinson's disease (PD) and their potential for repurposing. However, the conclusions drawn from these studies are not entirely consistent. To address this inconsistency, we used the two-sample Mendelian randomization (MR) method to explore the putative causal relationships between 23 medications and the risk and progression of PD. We applied inverse-variance weighted meta-analysis (IVW) to combine MR estimates. Additionally, sensitivity analyses were conducted to evaluate the robustness of the results. Our genetic evidence suggests that thyroid preparations and calcium channel blockers reduce the risk of PD, and salicylic acid and derivatives slow the progression of PD motor symptoms. Additionally, genetic evidence also suggests that four medications were associated with PD risk or progression, but the sensitivity analysis revealed that three of the medications may have interference caused by reverse causality. Our findings suggest that there are weak causal relationships between several medications and the risk or progression of PD. Though further replication studies are needed to verify these findings, these new insights may help in understanding the etiology of the disease, generate new clues related to drug discovery, and quantify the risk of future drug intake.
引用
收藏
页数:11
相关论文
共 65 条
  • [51] Mendelian randomization
    Sanderson, Eleanor
    Glymour, M. Maria
    Holmes, Michael V.
    Kang, Hyunseung
    Morrison, Jean
    Munafo, Marcus R.
    Palmer, Tom
    Schooling, C. Mary
    Wallace, Chris
    Zhao, Qingyuan
    Smith, George Davey
    [J]. NATURE REVIEWS METHODS PRIMERS, 2022, 2 (01):
  • [52] Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives
    Schapira, Anthony H. V.
    Olanow, C. Warren
    Greenamyre, J. Timothy
    Bezard, Erwan
    [J]. LANCET, 2014, 384 (9942) : 545 - 555
  • [53] Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
    Schwarzschild, Michael A.
    Ascherio, Alberto
    Casaceli, Cindy
    Curhan, Gary C.
    Fitzgerald, Rebecca
    Kamp, Cornelia
    Lungu, Codrin
    Macklin, Eric A.
    Marek, Kenneth
    Mozaffarian, Dariush
    Oakes, David
    Rudolph, Alice
    Shoulson, Ira
    Videnovic, Aleksandar
    Scott, Burton
    Gauger, Lisa
    Aldred, Jason
    Bixby, Melissa
    Ciccarello, Jill
    Gunzler, Steven A.
    Henchcliffe, Claire
    Brodsky, Matthew
    Keith, Kellie
    Hauser, Robert A.
    Goetz, Christopher
    LeDoux, Mark S.
    Hinson, Vanessa
    Kumar, Rajeev
    Espay, Alberto J.
    Jimenez-Shahed, Joohi
    Hunter, Christine
    Christine, Chadwick
    Daley, Aaron
    Leehey, Maureen
    de Marcaida, J. Antonelle
    Friedman, Joseph Harold
    Hung, Albert
    Bwala, Grace
    Litvan, Irene
    Simon, David K.
    Simuni, Tanya
    Poon, Cynthia
    Schiess, Mya C.
    Chou, Kelvin
    Park, Ariane
    Bhatti, Danish
    Peterson, Carolyn
    Criswell, Susan R.
    Rosenthal, Liana
    Durphy, Jennifer
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (10): : 926 - 939
  • [54] Educational attainment, structural brain reserve and Alzheimer's disease: a Mendelian randomization analysis
    Seyedsalehi, Aida
    Warrier, Varun
    Bethlehem, Richard A. I.
    Perry, Benjamin I.
    Burgess, Stephen
    Murray, Graham K.
    [J]. BRAIN, 2023, 146 (05) : 2059 - 2074
  • [55] Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease A Randomized Clinical Trial
    Simuni, Tanya
    Fiske, Brian
    Merchant, Kalpana
    Coffey, Christopher S.
    Klingner, Elizabeth
    Caspell-Garcia, Chelsea
    Lafontant, David-Erick
    Matthews, Helen
    Wyse, Richard K.
    Brundin, Patrik
    Simon, David K.
    Schwarzschild, Michael
    Weiner, David
    Adams, Jaime
    Venuto, Charles
    Dawson, Ted M.
    Baker, Liana
    Kostrzebski, Melissa
    Ward, Tina
    Rafaloff, Gary
    [J]. JAMA NEUROLOGY, 2021, 78 (03) : 312 - 320
  • [56] 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?
    Smith, GD
    Ebrahim, S
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2003, 32 (01) : 1 - 22
  • [57] PhenoScanner: a database of human genotype-phenotype associations
    Staley, James R.
    Blackshaw, James
    Kamat, Mihir A.
    Ellis, Steve
    Surendran, Praveen
    Sun, Benjamin B.
    Paul, Dirk S.
    Freitag, Daniel
    Burgess, Stephen
    Danesh, John
    Young, Robin
    Butterworth, Adam S.
    [J]. BIOINFORMATICS, 2016, 32 (20) : 3207 - 3209
  • [58] Calcium, ageing, and neuronal vulnerability in Parkinson's disease
    Surmeier, D. James
    [J]. LANCET NEUROLOGY, 2007, 6 (10) : 933 - 938
  • [59] Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO
  • [60] 2-U